Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
66.5M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
54.8M
-
Shares change
-
+9.19M
-
Total reported value, excl. options
-
$97.9M
-
Value change
-
+$13.5M
-
Put/Call ratio
-
0.22
-
Number of buys
-
38
-
Number of sells
-
-23
-
Price
-
$1.79
Significant Holders of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) as of Q2 2024
74 filings reported holding RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q2 2024.
Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.8M shares
of 66.5M outstanding shares and own 82.46% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (12.9M shares), RA CAPITAL MANAGEMENT, L.P. (6.25M shares), Vivo Capital, LLC (5M shares), Octagon Capital Advisors LP (4.26M shares), VANGUARD GROUP INC (4.05M shares), BlackRock Inc. (3.97M shares), Deep Track Capital, LP (3.26M shares), FMR LLC (2.02M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), and Opaleye Management Inc. (1.48M shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.